Hello, everyone. Thanks for joining us for our next presentation at the UBS Global Healthcare Conference. We are very pleased to have Acadia Healthcare. We have Debbie Osteen, Chief Executive Officer, and David Duckworth, Chief Financial Officer, with us today. At this point, maybe just to kick it off, thanks for participating again. At this point, we are 10+ months into 2026. How has the year been so far? How have results differed from expectations? How would you characterize the earnings momentum as you exit 2026 and head into 2027?
Thank you for having us. I think in the first nine or 10 months, I guess it is about 10 now.
Right
I think we have made significant progress. We have exceeded our internal expectations, and we have real momentum going into 2027. My focus, since I have come back as CEO, has really been to strengthen the team, and I think we have been able to do that, ensuring we have the right people in the right position. I took a look at the operational structure and looked at just how we could speed up decision-making. I looked at geography and scope of responsibility, so we made some changes there. I think the team right now has a very strong sense of urgency as you think about where we are entering 2027. We have been able to build the occupancy at the new facilities, but also improve some of the legacy facilities that have been part of Acadia. So, I feel very good.
I think the third quarter, we had strong results, and we put out the $60 million of incremental EBITDA for next year, just based on where we see as we end the year, but also just a detailed plan for each of those new facilities that we brought on since 2023.
That's great. We had the midterm elections last week with the Democrats taking over both the House and the Senate. How does the changing political landscape change the company's outlook and strategy, if at all?
Yeah, I don't see a significant change in our strategy. I've always believed that both parties are important to what we do, and I think both, over my years of being in the behavioral part of the healthcare industry, both Democrats and Republicans have really worked with us. I don't think that's going to change. We're going to continue to work constructively with them, and in states where we think there may be possibility to improve access, that's what we're going to do.
Right. Great. Without getting ahead of formal guidance, when you think about moving into 2027, what are the major operating headwinds and tailwinds that we should think about and consider?
Yeah. For 2027, normal for the company, we'll provide our outlook as part of our fourth quarter call, which will be in February. We'll provide more detail at that point. But as Debbie mentioned, we have made tremendous progress this year, momentum as we've moved throughout the year. Expect that to continue going into next year. The most significant tailwind that we would highlight would be the incremental EBITDA contribution from our new facilities. The capacity that we've added as a company over the last four years has already started to translate into incremental earnings, but the real meaningful time that that really begins to happen is as we look ahead into 2027.
Have made a lot of progress on our new facilities and have a $60 million, as Debbie mentioned, EBITDA contribution from those new facilities relative to the earnings of those facilities as a group in 2026. There is a number of other tailwinds that we expect just from the ongoing momentum that our other facilities have, but that is the tailwind that we highlighted last week on our earnings call related to the new facilities. Then in terms of headwinds, the only item that we would highlight, more of a mathematical headwind, so to speak, is just thinking about out-of-period state-directed payment programs that the company has received in 2026. We received $11 million in the first quarter from Ohio and $26 million in the second quarter from Florida, both of those related to 2025 program years. So, $37 million there that related to the previous year.
I will say we have some upside in both of those states for the 2026 potential approval. Those have not been approved yet at the CMS level for Ohio and Florida for 2026. The way we think about and quantify the headwind might change a little bit as we get more clarity on the timing of those 2026 approvals. But there is $20 million of upside there, and not certain at this point whether that is a fourth quarter item or whether that will stretch into the beginning part of 2027.
Okay. No, that is good. That is helpful. Let us talk about volumes for a minute. Acute behavioral volume grew 7.5% in 3Q, with both newer hospitals and existing facilities contribute. Can you talk about what is driving that kind of growth? How much is just stronger underlying demand? How much is having beds available for demand that already existed? Anything else behind that that you call out?
Yeah, I mean, I think the acute service line performed extremely well. You mentioned the momentum we are seeing as the volumes have ramped. If you take the 2023 to 2025 cohort, occupancy is up 60%. So it has come up quite a bit from when we started the year. I do think part of it is the strong demand in the market, but also just the execution by the team. Our referral relationships are strong, but also you have to factor in our partners, which a good portion of the cohort beds from 2023, 2024, and 2025 really were partnerships. Many of them had either a unit or a facility. As we have been able to work with them to provide access to those patients, that has really made a big difference in just the acute volumes. You want to add anything, David?
I think that's right. Obviously, we've added a tremendous amount of bed capacity to the company. As Debbie mentioned, many of those are with partners that have moved beds over to our new partnerships. Also, we're in a better position to meet the demand in the markets that were in need of new beds. I think the geographic expansion that we're seeing, we're in more acute markets and better able to meet the already strong demand that was there.
The other dynamic is really around the legacy. We identified a group of facilities at the beginning of the year that were not performing where we thought they should and may have been down even from prior years. We came up with detailed plans around that, to how can we get them back to where they were, and how can we see growth? We've been seeing that, and certainly did in the third quarter.
Okay. I know one thing you've called out is the changes in New York Medicaid meant your Pennsylvania facilities no longer got those New York patients beginning in Q2. You've been trying to replace that volume with referrals from Pennsylvania and other areas. How far along in that process are you? How should we think about the remaining opportunity there as comparisons start to anniversary in the first half next year?
Yeah, that was an item that we called out at the beginning of the year. We had a significant referral source for our Pennsylvania facilities from New York Medicaid, and that's had an EBITDA impact to the company, as well as had a sort of an outsized impact, impacting our volume more than our earnings, just from the loss of those patients. We have made progress throughout the year. There's other demand that we're seeing within the Pennsylvania market, other referral sources, both within Pennsylvania as well as other states, and we've been able to backfill to some degree, and we're seeing that in just strong specialty performance this year. This has been a good year for our specialty service line, despite that headwind that they faced. We will see sort of the year-over-year anniversary of that issue as we start 2027.
We did see a small contribution of New York patients to our first quarter of 2026, but for the most part, we will see the full year anniversary of that challenge in the first quarter. We still think it's a positive as we move forward to have that capacity in our Pennsylvania facilities, and we're working to rebuild that referral source if that's an opportunity, just as we think about New York Medicaid, but also other demand and other referral source relationships that could provide a tailwind as we think about the specialty capacity that we have in our Pennsylvania facilities.
Okay. I think your commercial volume represented about 21% of the business in the 3Q, and you explained that some of the decline there was specialty facility closures, rather than a change in payer trends. As the newer acute care hospitals mature, and our capacity matures, and you add payer contracts, how should we think about payer mix in general and commercial in specific over the next 12 - 18 months?
Yeah, I think our commercial payer mix has been stable. You mentioned a couple of factors that impacted that with respect to closures that were done over the last couple of years. We have seen some growth in Medicaid at our acute facilities, but they've been in markets where we feel like the reimbursement is strong. We do have a team that works with referral sources, and a lot of the referral sources have commercial. We've got a few facilities, more than a few, that actually pull referrals from across the country, and so that's where we see more of the commercial mix in the specialty area.
Okay. On the acute side, as that becomes a bigger part of the business, you're seeing admissions grow faster than patient days because those days are generally shorter, so it's a mix effect. Within acute itself, what's happening in terms of admissions and length of stay? How should we think about those trends heading into 2027?
Yeah, that's right, and we've talked about that trend, just the service mix impact on our admissions and our length of stay metric. We've known that was coming as we've added acute beds to the business. The 16 new facilities that we talk about, and even many of our facility expansions, have been heavily weighted towards acute. It's 60% of our revenue today, and we think it could continue to grow as those new facilities continue to mature. We expect to see that trend moving forward, where the acute has a shorter length of stay. Our same-facility metrics reflect all of our service lines, so reduce that average length of stay. But within our acute business, length of stay has been stable. The admissions growth that we see and the patient day growth that we see, which we've talked about, that 7.5%, we think that will continue.
There's going to be just a really strong growth in the acute facilities over the next few years, and expect that service mix impact to continue to be reflected in the same facility metrics.
That's great. The new facilities opened this year have moved through the licensing, accreditation, and payer approvals faster, leading to earlier openings. Is this happening because the company's got some initiatives in place that are driving that, or is this being driven mainly by external factors?
No, I think that I give credit to the team. One thing we did together when I returned as CEO was look at what are the lessons learned from last year? What could we do differently? I think what we have done is we've come up with more consistency, and we developed a playbook that really focuses on who are the decision-makers for each of the states where we're opening facilities.
As I think about this year and the four new facilities, hospitals that we opened, we cut the time in half, and we actually had record time for accreditation at our facility in Orlando and our facility in Iowa, which makes a difference because if we are able to move through the accreditation process faster and get the payer contracts and CMS works with us to get Medicare and Medicaid, then it just allows us to treat patients quicker, because it is not like the volume is not there.
It is just we, last year, had a number of openings, and it took a lot more time than I think anyone expected. We are very focused on it. Each state, we have a list. The other thing that is different, A.J., is we are really working with our partners, and I do not think we did that to the extent that we could have. Now, if we see a slowing of any of those steps, we are asking for their assistance, because they are important in the market and many times very important in the state. Really working together with them.
Oh, interesting. Okay. As you said earlier, you outlined and put some takes on next year. One of the things is $60 million of additional EBITDA from the newer hospitals in 2027. When you think about that, are you making any assumptions on occupancy gains that are faster than normal, lower than normal? What other improvements are you anticipating on that $60 million? Do you think that builds steadily over the course of the year, or is it something that happens relatively quickly and then sort of plateaus?
Occupancy gains absolutely are the key driver of the $60 million of incremental EBITDA. What we have seen throughout this year, we have made great progress this year. The new facilities, the four that have opened this year, have very low occupancy in their early stages of being open, focusing on getting through the licensing, the survey accreditation, and now being on to payer contracting, and being at a point where they will start to ramp their occupancy in a more significant way. What we see is the startup losses that those new facilities incur start to go towards break-even and then towards a positive EBITDA number because the cost structure is established and is driving the startup losses that we see today.
Then as the occupancy grows, it will drive those new facilities towards break-even results, which our goal generally is to be around break-even after a year. It depends on the facility, but it takes getting to about 35%-40% occupancy to be at break-even, again, depending on the facility, the market, and other dynamics. But the facilities that are further along because they opened from 2023 to 2025, those facilities are also in a great position to continue to grow their occupancy. They've already made a lot of progress this year. But the impact from those facilities is also significant, especially 2025 facilities. We've highlighted that as a year where we had the most beds, and we had five of the 16 facilities. And those facilities have made a tremendous amount of progress this year.
They were at varying levels of ramp-up as we started the year, having opened throughout last year, and some of them were a little bit behind schedule and have made progress over the course of the year to put them in a position to really see the EBITDA benefit of continued occupancy ramp at those facilities.
Okay. As part of the initiative to refocus on the core business, you did pull back on some of your, or at least the pacing of new development that the previous team had in place. Having said that, do you have any early estimate on, while you're not doing new joint ventures per se right now, how many bed additions in existing facilities you might consider for 2027? Is that something you've got?
Well, we're in process right now of preparing the budget.
Okay
For 2027, so we will be providing detail on our call in February. We regularly review our opportunities. When a facility gets to 75% occupancy, they really start turning away patients because you have age components and you have male and female. We have a pipeline for expansion beds, which is the best return on our capital. I think we have talked about 100 - 200 beds. We have a regular look at each facility, where they are at with occupancy, do we have the ability to expand on the site? That will be part of what we will talk about in February. It is attractive to expand a bed because you are using the overhead is there, and obviously you are probably turning away patients.
Right.
That would be our first use of capital, particularly next year.
Okay. Specialty revenue was down on a reported basis, but grew in the low single digits after adjusting for closures in the New York impact, that we talked about earlier. What does the remaining specialty portfolio look like today, and where do you see its role in Acadia's overall portfolio and growth over the next few years?
Yeah. We really like our specialty service line, and we have it is about 15% of our revenue. We have just under 30 facilities. What we see in those facilities, and many specialty facilities are in our existing acute markets, really able to connect our service lines and provide benefits to just a broader set of patients in those markets. Many of our facilities also have a nationwide pull. People travel to be treated within our specialty service line. But like it from a diversification perspective, the expertise that we have within those facilities and the service offerings and the variety in those service offerings. We like to just be able to treat more patients and find the right facility for their clinical needs, and think we are able to do that with the capabilities that we bring within our specialty facilities.
They have had the two headwinds this year, the New York Medicaid change as well as closures that happened last year. If you adjust for those, they have had a good year, just over 2% growth on a year-over-year basis.
It is not unusual for there to be some new people that are new to the Acadia story in a group like this. Just to put a finer point on the specialty comment, what are some of the service lines, if someone is new to you guys, what are some of the things you do in those specialty facilities?
Well, we treat substance use, but in some of the facilities, there is also a comorbidity that goes along with it. So, you may be using alcohol or drugs, but you also have an issue that is related more to a mental health issue.
Okay.
Sometimes you treat the substance use first, then you address the mental health aspect, where it might be depression or other things. It is interesting, if you think about specialty, it is really a broad range of services that you will see. We have some women's programs, we have some that even refine that even more. Then we have a group, where, as New York as an example, where it may be mainly Medicaid patients. As I mentioned and David mentioned, some of the others might pull more from a commercial mix, where people would look and see, and they look on the internet, they are shopping for the best program.
We have been able, through our outcomes, to really show the referral sources that by sending a patient to us, they are going to be not just contained with the substance use, but also treating that other piece, which is the mental health aspect.
Okay. You have increased operational efficiency and reduced some costs in your CTC service line over the last few quarters. Can you walk us through exactly what you have changed and where you are at in terms of further opportunities that remain?
Yeah. The CTC service line, we have talked about just seeing some variability. We are in 33 states, have a really good footprint, great team that oversees that business nationwide, but then within each of our markets. What the team has been able to do this year is to just find some cost efficiencies to mitigate the revenue performance. The revenue has been flattish throughout the year, and they have been able to identify cost efficiencies and reductions in certain markets, but then also across the business to mitigate some of the revenue headwinds that we have managed through throughout the year.
They have also, I think what they have done a good job in terms of positioning us for revenue growth, just been able to rethink how do we perform, how do we provide the right patient experience, patient focus, share best practices across our markets? How do we think about marketing spend? That has been one source of not only cost efficiency, but also thinking about some of the volume opportunities that we think are there for that business going forward. So they have been able to think about the cost management and efficiency in a way that has offset some of the revenue challenges that we have seen, but also the position and strength in the service line for future growth.
Yeah. Maybe pivoting over to payer mix and revenue cycle for a second. You saw steady progress, you said, in your revenue cycle initiatives through Q3, and expect continued progress in Q4. What are some of the things you are doing, documentation, technology, AI-related, that are driving some of that?
Yeah. It has been good to see throughout the year stability in our revenue cycle. About a year ago, in the third quarter of 2025, the company saw an elevated level of bad debts and denials. A lot of that was just payer activity that has always been there for the business. I think an opportunity to also strengthen our internal processes and investments in our people and our processes, and also use technology. What we have been able to do this year, the team has done really a fantastic job driving improvement. We have been able to ensure we have the tools to have immediate visibility into what is happening in our markets and in our facilities.
Being able to monitor our key revenue cycle metrics, identify when there is a challenge, and intervene quickly, which is important with our payers to have a real-time identification and timely follow-up in order to drive improvement with those payers. Going forward, I think part of our focus is just on having a very high quality in our documentation. We think part of it is just payers holding us appropriately to a high standard, and some payers have their own requirements in terms of processes that we go through throughout providing care to the patients. We have been able to strengthen our documentation and our processes, and having electronic medical records for the company, I think, has put us in a stronger position.
It is not always been something the company had, but is invested in, and by early 2027, we will have EMRs in all of our acute facilities, which is a real positive in terms of documentation, having data that can then do the basics, revenue cycle, but then also create other opportunities for what we can do with that data, engaging with payers, making decisions internally, et cetera.
Good. I know you said that several rate increases had taken effect in July, and you described those in acute behavioral business as being in the low single digits. How are conversations going with payers and states? States have to implement the OBBBA, which I know doesn't have any direct, necessarily, impact on you guys, but it obviously could put pressure on state budgets. Both from a commercial and a Medicaid mix, what are you seeing and what are you hearing on that?
Yeah. Our goal is to be collaborative with the payers, and there's always the push and pull that I've seen for years. There have been a variety of times over the years that I've been in the business where the Medicaid budgets come under pressure. It's our job to continue to demonstrate what we do and the importance of mental health and how it has an impact on medical.
Right.
And how those costs can be a factor as they look at their overall budget. We don't think that the work requirements will impact us in a significant way. As you mentioned, A.J., I think that the majority of our patients that have either substance use or a disabling mental illness will be exempt. Each state is setting these procedures and how they're going to handle this, so we're working very closely with them to ensure that our patients that have these issues are exempt. So far, the states that we've seen actually putting in procedures and policies, they are allowing self-attestation rather than making it a complicated process for the patient to actually show that they have this disabling condition. We've seen some strong, and you mentioned that we've seen some rate increases, not just in acute, but even in RTC this year.
I think that, yes, there is pressure, but I think we're also staying very close to who we believe the decision-makers are as they decide what rate increases will look like going forward.
Okay. A few years ago, labor was a constraint on growth and a pressure point. It sounds like that's stabilized considerably. When you look at 2027 versus 2026, anything that you see is changing the dynamic on staffing, wages, retention, any of that?
It has been a positive and a stable labor environment for the company, allowing us, as we've always been able to do, to add staffing as we expand a facility or as we open a new facility. The just year-over-year increases have been more normal than I know they were in that period you're referring back to.
Right
Several years ago. We do believe we're in a positive labor environment, and we want to continue to invest, and we think there's actually opportunity as we move forward to just improve employee retention, continue to train and find the right employees for our facilities. So, we've been really pleased that it's been a stable labor environment and think that that gives the company some opportunities on employee retention and engagement as we move forward. There's no significant changes based on how we look at our different markets as we move into 2027.
I mean, as you think about us compared to other companies in the behavioral space, we have a centralized recruiting function, and I think that's made a difference. It certainly did during the COVID years, but also continuing as we open all of the new hospitals. So, they have done a very good job of identifying what we need to open and also making sure that we, as people, we have turnover, that those positions are filled so we're not limiting growth because of staff.
Okay. Professional and general liability expenses were about $27 million-$28 million in 3Q. That is consistent with the expectations you have laid out. Obviously, that was still above last year. With another actuarial review, I think, coming in fourth quarter, what will matter most in assessing the 2027 outlook and where are your incident prevention efforts and so forth?
Well, we do have a number of efforts in place to improve that cost and what we have seen over the last couple of years, and believe those efforts will drive improvement going forward. They are focused on minimizing incidents, which includes employee oversight, training, everything that happens within the culture and the leadership and processes at our facilities, as well as what we do on the back end to manage incidents when they do happen, have good legal resources, and are willing to be aggressive and strategic with how we defend the company. It is a case-by-case decision as we think about where that makes sense, but feel like we have good resources and focus and initiatives to drive improvement going forward.
In terms of your question, what matters the most going into the fourth quarter review, our fourth quarter actuarial review follows a mid-year review that we completed this year, which was a change that we made going into 2026. It is a comprehensive review, including the number of incidents we have seen this year, which has tracked according to the forecast that we had for the year. There are other parts of the review that we will go through in the fourth quarter and provide an update around that in February.
Okay. The outpatient payment rule came out last week, finalized. I know this is sort of tangential to you, but anything in there that is worth highlighting or makes any difference really?
It's not really a significant driver for us.
Okay.
But I think it's maybe like 500,000. It's not a big mover for us.
Okay. No, that's fine. When you think about where you're at with cash flow, free cash flow, $47 million in third quarter, you paid down $63 million of debt, prioritizing investing in the business, debt reduction, other future growth. How should we think about that? Any quick comments there?
Yeah. We are in just a very strong position to have a good year of free cash flow, the reduction in the CapEx plan that happened around a year ago, as well as our performance this year. Just seeing progress throughout our facilities has put us in a strong position, and really view the next few years as we have a strong runway of growth and from the capacity that we have. So, incremental earnings and cash flow combined with the capital reduction, and ongoing expectations that operating cash flow will be available to the company.
How we think about that is we will have the debt repayment opportunities, but a lot of strategic flexibility as we look ahead in terms of where we can continue to make growth investments, but do that from a disciplined perspective according to what is most attractive to the company in each of our markets. A positive outlook continues over the next few years.
We have got those that sit at the facilities as well as those that are in higher positions and operations. We have got everyone focused on return on investment with respect to capital and how it is used.
Yeah, of course. I think that we need to wrap it up. I appreciate Acadia participating once again. I think next up in here we have Health Care Service Corporation, the largest Blue Cross Blue Shield provider in the U.S. Thanks.
Thank you, A.J.